Form 4: TransMedics Group Executive Tamer Khayal Executes Stock Options and Sells Shares Under 10b5-1 Plan
SEC Form 4
Chief Commercial Officer of TransMedics Group, Tamer Khayal, exercised stock options and sold shares of common stock on May 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On May 1, 2024, Tamer Khayal, Chief Commercial Officer of TransMedics Group, exercised stock options to acquire shares of common stock.
- The exercises involved 45,326 shares at a price of $38.46, 1,458 shares at $38.46, and 1,083 shares at $13.28.
- Concurrently, Khayal sold a total of 49,821 shares of common stock at prices ranging from $105.96 to $123.66.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan established on September 6, 2023.
- Following these transactions, Khayal directly owns 9,892 shares and indirectly owns 7,888 shares through the Khayal Family 2021 Irrevocable Trust and 11,051 shares through the Tamer Ibrahim Ahmed Khayal Trust.
- Khayal also holds options to purchase 16,042 shares at $38.46 and 23,834 shares at $13.28.
Sentiment
Score: 5
Explanation: The document is a routine disclosure of stock transactions by an executive, with no inherent positive or negative sentiment. It reflects standard corporate governance practices.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies, often governed by pre-arranged trading plans like Rule 10b5-1 to avoid accusations of insider trading. These transactions can be influenced by factors such as company performance, market conditions, and personal financial planning.
Comparison to Industry Standards
- Executive compensation packages often include stock options as a way to align management's interests with those of shareholders.
- Rule 10b5-1 plans are a standard tool used by executives to manage their stock holdings in a transparent and compliant manner.
- The vesting schedules and exercise prices of the options are typical for the industry.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-arranged nature of the sales mitigates concerns about insider information.
Key Dates
| Date | Description |
|---|---|
| 2021-02-24 | Vesting commencement date for stock options, vesting monthly until fully vested on the fourth anniversary. |
| 2023-09-06 | Date of entry into the Rule 10b5-1 trading plan. |
| 2024-05-01 | Date of the reported transactions (option exercise and stock sales). |
| 2031-02-24 | Expiration date for stock options. |
| 2032-02-22 | Expiration date for stock options. |
| 2024-05-03 | Date of signature of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.